{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:00:57Z","timestamp":1787504457243,"version":"build-2736575974"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"United States Division of Tuberculosis Elimination"},{"name":"National Center for HIV\/AIDS"},{"name":"Viral Hepatitis"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA054174"],"award-info":[{"award-number":["P30 CA054174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Therapy and Research Center at the University of Texas Health Science Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rifapentine exposure is associated with bactericidal activity against Mycobacterium tuberculosis, but high interindividual variation in plasma concentrations is encountered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate a genomic association with interindividual variation of rifapentine exposure, SNPs of six human genes involving rifamycin metabolism (AADAC, CES2), drug transport (SLCO1B1, SLCO1B3) and gene regulation (HNF4A, PXR) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We characterized these genes in 173 adult participants in treatment trials of the Tuberculosis Trials Consortium. Participants were stratified by self-identified race (black or non-black), and rifapentine AUC from 0 to 24\u2009h (AUC0\u201324) was adjusted by analysis of covariance for SNPs, rifapentine dose, sex, food and HIV coinfection. This study was registered at ClinicalTrials.gov under identifier NCT01043575.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The effect on rifapentine least squares mean AUC0\u201324 in black participants overall decreased by \u201310.2% for AADAC rs1803155 G versus A allele (Wald test: P\u2009=\u20090.03; false discovery rate, 0.10). Black participants with one G allele in AADAC rs1803155 were three times as likely to have below target bactericidal rifapentine exposure than black participants with the A allele (OR, 2.97; 95% CI: 1.16, 7.58). With two G alleles, the OR was greater. In non-black participants, AADAC rs1803155 SNP was not associated with rifapentine exposure. In both black and non-black participants, other evaluated genes were not associated with rifapentine exposure (P\u2009&amp;gt;\u20090.05; false discovery rate &amp;gt;\u20090.10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rifapentine exposure in black participants varied with AADAC rs1803155 genotype and the G allele was more likely to be associated with below bactericidal target rifapentine exposure. Further pharmacogenomic study is needed to characterize the association of the AADAC rs1803155 with inadequate rifapentine exposure in different patient groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaa490","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T15:15:14Z","timestamp":1604934914000},"page":"582-586","source":"Crossref","is-referenced-by-count":22,"title":["Decreased plasma rifapentine concentrations associated with\n                    <i>AADAC<\/i>\n                    single nucleotide polymorphism in adults with tuberculosis"],"prefix":"10.1093","volume":"76","author":[{"given":"Marc","family":"Weiner","sequence":"first","affiliation":[{"name":"University of Texas Health Science Center San Antonio, San Antonio, TX, USA"},{"name":"South Texas Veterans Health Care System, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Gelfond","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa L","family":"Johnson-Pais","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Engle","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L","family":"Johnson","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA"},{"name":"Uganda\u2013Case Western Reserve University Research Collaboration, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Whitworth","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Bliven-Sizemore","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pheona","family":"Nsubuga","sequence":"additional","affiliation":[{"name":"Uganda\u2013Case Western Reserve University Research Collaboration, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Dorman","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada","family":"Savic","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Pharmacokinetics\/Pharmacodynamics Group of Tuberculosis Trials Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pheona","family":"Nsubuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ricaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"2021021208595125900_dkaa490-B1","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/infdis\/jis461","article-title":"Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium","volume":"206","author":"Dorman","year":"2012","journal-title":"J Infect Dis"},{"key":"2021021208595125900_dkaa490-B2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2021021208595125900_dkaa490-B3","journal-title":"Contemp Clin Trials"},{"key":"2021021208595125900_dkaa490-B4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2021021208595125900_dkaa490-B5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"2021021208595125900_dkaa490-B6","doi-asserted-by":"crossref","first-page":"e00210.-17","DOI":"10.1128\/AAC.00210-17","article-title":"Genetic determinants of the pharmacokinetic variability of rifampin in Malawian adults with pulmonary tuberculosis","volume":"61","author":"Sloan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208595125900_dkaa490-B7","doi-asserted-by":"crossref","first-page":"e01964-18","DOI":"10.1128\/AAC.01964-18","article-title":"A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine","volume":"63","author":"Francis","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208595125900_dkaa490-B8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/jac\/dkt036","article-title":"Relationship between CES2 genetic variations and rifampicin metabolism","volume":"68","author":"Song","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021021208595125900_dkaa490-B9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejps.2015.07.006","article-title":"Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases","volume":"78","author":"Fukami","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"2021021208595125900_dkaa490-B10","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/AAC.00353-10","article-title":"The effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations","volume":"54","author":"Weiner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208595125900_dkaa490-B11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nprot.2010.182","article-title":"Basic statistical analysis in genetic case-control studies","volume":"2","author":"Clarke","year":"2011","journal-title":"Nat Protoc"},{"key":"2021021208595125900_dkaa490-B12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.32614\/RJ-2018-001","article-title":"A system for an accountable data analysis process in R","volume":"10","author":"Gelfond","year":"2018","journal-title":"R J"},{"key":"2021021208595125900_dkaa490-B13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1124\/dmd.109.026567","article-title":"Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis","volume":"37","author":"Watanabe","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"2021021208595125900_dkaa490-B14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1124\/dmd.111.043877","article-title":"Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice","volume":"40","author":"Zhang","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"2021021208595125900_dkaa490-B15","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1128\/AAC.00345-10","article-title":"Effects of four different meal types on the population pharmacokinetics of single dose rifapentine in healthy male volunteers","volume":"54","author":"Zvada","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208595125900_dkaa490-B16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2021021208595125900_dkaa490-B17","doi-asserted-by":"crossref","first-page":"e147\u201395","DOI":"10.1093\/cid\/ciw566","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021021208595125900_dkaa490-B18","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/cid\/ciz942","article-title":"Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis","volume":"70","author":"Alfenaar","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/582\/36241033\/dkaa490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/582\/36241033\/dkaa490.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T19:33:13Z","timestamp":1613158393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/3\/582\/6055076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,29]]},"published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa490","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,12,29]]}}}